New hope for kids with deadly brainstem glioma? early safety trial completed.

NCT ID NCT01165333

First seen Mar 22, 2026 · Last updated May 10, 2026 · Updated 10 times

Summary

This early-phase study tested the safety of a drug called cilengitide when given together with radiation therapy for children and young adults with a rare, aggressive brain tumor called diffuse intrinsic pontine glioma (DIPG). The main goal was to find the highest safe dose of cilengitide. 32 participants took part, and the study focused on tracking side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU

    Toulouse, 33059, France

  • CHU, Hôpital d'Enfants de la Timone

    Marseille, 13385, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, 44093, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital des Enfants, Groupe Hospitalier

    Bordeaux, 33076, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Institut Curie

    Paris, 75231, France

  • Institut Gustave-Roussy

    Villejuif, 94805, France

Conditions

Explore the condition pages connected to this study.